TABLE 2.
Characteristics of Treatment with the Study Drugs
| Characteristics | Patients, n = 47 (%) |
|---|---|
| Number of cycles | |
| Median | 8 |
| Range | 1–42 |
| Treatment interruption | |
| Disease progression | 32 (68.1) |
| Adverse events or toxicity | 7 (14.9 |
| Dose reduction | 34 (72.3) |
| GSCF | 7 (14.9) |
GSCF, granulocyte colony-stimulating factor.